Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
This personalized approach ensures an optimal balance in harnessing the benefits of these injections over time
sbb-itb-a7208f6 Safety Information This section outlines the safety profile and guidelines for IV glutathione therapy
:
Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases
Treatment should be discontinued after 12 weeks on the maintenance dose if patients have not lost at least 5% of their initial body weight
US$ 22.32
US$ 26.21
US$ 22.57
US$ 26.45
